GeneDx Posts $0.28 EPS Beat but Trims Volume Outlook to 28%

GeneDx beat the quarter and cut the growth rate — both in the same report. The genomic diagnostics company posted third-quarter earnings of $0.28 per share on Monday, clearing the $0.07 consensus by $0.21, on revenue of $123.10 million versus the $122.93 million analysts expected, per FiscalAI. A year ago, the same quarter produced a loss of $0.27 per share.

Behind the headline beat, the picture tightens. The company reported $8.6 million in adjusted net income and a 72% adjusted gross margin (gross profit as a share of revenue, excluding one-time items). It raised full-year adjusted gross margin guidance to roughly 71% and lifted adjusted net income guidance to at least $12 million. Revenue guidance stayed at $475 million–$490 million — but management now expects results at the low end of that band.

The constraint is administrative, not clinical. GeneDx trimmed its full-year exome and genome volume growth outlook to at least 28%, from a higher prior target, and revenue growth to at least 17%, citing new requirements to collect payer documentation before running tests. Accessions grew 28% year over year against 25% growth in reported test volume. Management said most of that gap reflects delays, though some orders may be canceled. The takeaway: volume is arriving, just later.

What's working in the revenue cycle?

Collections are improving fast. Outpatient genome collection rates rose to 36% in the third quarter, up from 32% in the second. The blended average reimbursement rate climbed 5% sequentially to $3,436. Management said most denials it analyzed were administrative or procedural, and it expects further gains as new processes and technology come online.

Demand grew across markets. The GenPeds sales team is already paying for itself, management said, and could become the company's largest single customer segment by volume in 2027. The biopharma and data business grew for a second consecutive quarter, adding Mirum Pharmaceuticals and Beren Therapeutics as sponsored-testing partners.

One structural item looms: management expects PAMA changes (federal lab-reimbursement rate revisions under the Protecting Access to Medicare Act) to create a mid-single-digit headwind to total revenue in 2027, with about 45% of revenue exposed. The company expects revenue-cycle improvements to more than offset that pressure, but it did not issue 2027 guidance.

How did the market and insiders react?

Shares of WGS opened at $54.83 on Wednesday. The stock carries a $1.64 billion market cap, a price-to-earnings ratio of -14.51 and a beta of 2.00. It trades below its 50-day moving average of $75.82 and 200-day moving average of $70.91, with a 52-week range of $32.21 to $170.87. The balance sheet shows a current ratio of 3.30, a quick ratio of 3.06 and a debt-to-equity ratio of 0.40.

Insider activity was mechanical rather than directional. CEO Katherine Stueland sold 10,501 shares on Wednesday, September 16, at an average of $97.61 — a total of $1,025,002.61 — leaving her with 115,476 shares worth about $11.27 million. CFO Kevin Feeley sold 3,728 shares the same day at the same average price, for $363,890.08, leaving 44,945 shares worth roughly $4.39 million. Both sales covered tax withholding obligations tied to vesting equity awards, per SEC filings. Over the last 90 days, insiders sold 19,206 shares worth $1,808,056; insiders still own 25.17% of the stock.

Options desks noticed the uncertainty. Put-option trading hit 6,604 contracts, roughly 255% above typical daily volume, per Schaeffers Research — a signal of elevated demand for downside protection.

Where do analysts stand?

The ratings split is wide. BTIG Research restated a buy with an $85.00 price objective, cut from $90.00. Guggenheim raised its target from $74.00 to $83.00 with a buy rating on October 1. Zacks downgraded the stock from strong-buy to hold on October 9, and Wall Street Zen upgraded from sell to hold on August 8. Weiss Ratings reiterated a sell on November 2. Across seven buy ratings, one hold and one sell, MarketBeat tallies an average rating of Moderate Buy and an average price target of $90.14.

Founded in 2000 by National Institutes of Health researchers, GeneDx specializes in whole exome and genome sequencing for rare and inherited disease diagnosis, plus hereditary cancer risk testing. The quarter proved the model can print adjusted profit — the question for 2027 is whether collections can outrun the reimbursement math.